Establishment of ketogenic diet therapy guidance in Japanese patients with ADPKD - Ketogenic diet therapy in Japanese ADPKD

Department of Urology, Juntendo University Graduate School of Medicine0 sites100 target enrollmentNovember 27, 2023

Overview

Phase: 未知
Intervention: Not specified
Conditions: Autosomal dominant polycystic kidney
Sponsor: Department of Urology, Juntendo University Graduate School of Medicine
Enrollment: 100
Status: Not yet recruiting
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

November 27, 2023

End Date

October 18, 2025

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Department of Urology, Juntendo University Graduate School of Medicine

•(1\) poorly controlled diabetes mellitus with HbA1C \> 8\.0 (2\) Uncontrolled dyslipidemia with LDL cholesterol \> 4 mmol/L or triglycerides \> 3 mmol/L (3\) Uncontrolled hypertension (SBP \> 160 and/or BP \> 100 mm Hg on 3 occasions) (5\) Hyperkalemia (\>5\.5 mmol/l). (6\) Significant disease such as malignancy within the past 5 years, autoimmune disease under immunosuppressive treatment (8\) On any medication (SGLT2 inhibitor) or investigational drug that may affect the safety of the ketogenic diet (since bardoxolone methyl for ADPKD is under investigation in Japan). (12\) Food sensitivities or allergies incompatible with the nutritional program (13\) Subject is already compliant with a ketogenic diet or fasting (14\) Current or past history of eating disorders or eating behaviors (16\) Ulcerative colitis, irritable bowel syndrome, Crohn's disease, or gallbladder disease (17\) BMI less than 18